Telemus Capital’s Novavax NVAX Stock Holding History

Telemus Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3,110	Closed	-$333K	–	413
2020 Q3	$333K	Buy	+3,110	New	+$379K	0.02%	357

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Telemus Capital's NVAX Position: Q4 2020 in Review

Telemus Capital sold out of Novavax (NVAX) in Q4 2020, closing a stake of 3,110 shares — an estimated $333K sold.

Telemus Capital first reported a position in NVAX in Q3 2020 and held it in 1 quarter. The position peaked at $333K in Q3 2020. 347 funds tracked by Wall St. Rank hold NVAX as of Q4 2020.

Telemus Capital reported no remaining Novavax position as of Q4 2020 after selling out during the quarter.
Telemus Capital sold 3,110 Novavax shares in Q4 2020, an estimated $333K.
Telemus Capital first reported a position in Novavax in Q3 2020 and held it in 1 quarter.
Telemus Capital's Novavax position peaked at $333K in Q3 2020.
347 funds tracked by Wall St. Rank held Novavax as of Q4 2020.

Based on Telemus Capital's 13F filing for Q4 2020, filed 28 Jan 2021.